retatrutide glp-1 gip glucagon receptor agonist triple Sweet Temptation, bitter Truth: Diabetes in the Research Spotlight LY3437943, a novel triple glucagon,
Description
About 6 to 10 extra cases per 10,000 users over 3 years
The best studied and current cornerstone of treatment for NAFLD is weight loss
Patients should be counselled to expect these potential side-effects
01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
It is used in type 2 diabetes and is also known for producing stronger weight-loss effects
The growth of this market is mostly driven by the presence of a robust R&D pipeline, improved efficacy offered by GLP-1 drugs, and the high demand from end users
